Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJ NYSE:NVS OTCMKTS:RHHBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$230.61+0.1%$235.49$147.33▼$251.71$554.67B0.277.67 million shs6.97 million shsNVSNovartis$149.85+0.1%$151.32$106.71▼$170.46$285.75B0.461.42 million shs1.52 million shsRHHBYRoche$51.29+0.1%$50.83$35.07▼$60.85$326.55B0.52.49 million shs1.19 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+0.08%+3.70%-3.97%-5.24%+57.53%NVSNovartis+0.09%+3.03%-2.32%-8.12%+42.47%RHHBYRoche+0.06%+1.39%+0.51%-12.34%+37.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$230.61+0.1%$235.49$147.33▼$251.71$554.67B0.277.67 million shs6.97 million shsNVSNovartis$149.85+0.1%$151.32$106.71▼$170.46$285.75B0.461.42 million shs1.52 million shsRHHBYRoche$51.29+0.1%$50.83$35.07▼$60.85$326.55B0.52.49 million shs1.19 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+0.08%+3.70%-3.97%-5.24%+57.53%NVSNovartis+0.09%+3.03%-2.32%-8.12%+42.47%RHHBYRoche+0.06%+1.39%+0.51%-12.34%+37.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.74Moderate Buy$253.049.73% UpsideNVSNovartis 2.31Hold$141.20-5.77% DownsideRHHBYRoche 2.45Hold$51.500.41% UpsideCurrent Analyst Ratings BreakdownLatest JNJ, RHHBY, and NVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.004/29/2026NVSNovartis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (A-) ➝ Buy (B)4/24/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)4/24/2026RHHBYRoche Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$46.004/20/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$244.00 ➝ $266.004/16/2026JNJJohnson & Johnson ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$240.00 ➝ $275.004/16/2026JNJJohnson & Johnson Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$237.00 ➝ $246.004/15/2026JNJJohnson & Johnson Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$283.004/15/2026JNJJohnson & Johnson Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$265.004/15/2026JNJJohnson & Johnson Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$220.00 ➝ $250.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$94.19B5.89$14.13 per share16.32$33.73 per share6.84NVSNovartis$54.53B5.24$10.75 per share13.94$20.40 per share7.35RHHBYRoche$76.45B4.27$3.60 per share14.24$7.18 per share7.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$26.80B$8.6526.6618.332.2621.83%32.60%13.29%7/15/2026 (Estimated)NVSNovartis$13.98B$6.9821.4715.242.6324.87%38.82%15.16%7/21/2026 (Estimated)RHHBYRoche$15.55BN/AN/A14.614.22N/AN/AN/A7/23/2026 (Estimated)Latest JNJ, RHHBY, and NVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billion4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.202.25%+5.25%60.12%64 YearsNVSNovartis$3.082.06%+5.28%44.13%N/ARHHBYRoche$0.971.89%N/AN/AN/ALatest JNJ, RHHBY, and NVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.461.030.77NVSNovartis0.960.850.65RHHBYRoche0.721.381.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVSNovartis13.12%RHHBYRocheN/AInsider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVSNovartis0.01%RHHBYRocheN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableNVSNovartis75,2671.91 billion1.91 billionOptionableRHHBYRoche103,2496.37 billionN/ANot OptionableJNJ, RHHBY, and NVS HeadlinesRecent News About These CompaniesRoche gets second European approval for Alzheimer's testMay 12 at 1:05 AM | reuters.comRoche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)May 12, 2026 | globenewswire.comErste Group Bank Analysts Lift Earnings Estimates for RocheMay 8, 2026 | marketbeat.comF. Hoffmann-La Roche Ltd: Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnosticsMay 7, 2026 | finanznachrichten.deRoche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics ToolsMay 7, 2026 | wsj.comSwitzerland's Roche agrees to acquire US-based PathAIMay 7, 2026 | reuters.comRoche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnosticsMay 7, 2026 | globenewswire.comFY2026 EPS Estimates for Roche Raised by Erste Group BankApril 30, 2026 | marketbeat.comGenentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026April 30, 2026 | businesswire.comRoche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026April 30, 2026 | globenewswire.comBiogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A CostsApril 29, 2026 | zacks.comRoche Holding AG (OTCMKTS:RHHBY) Sees Large Decrease in Short InterestApril 29, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding (OtherRHHBY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)April 25, 2026 | theglobeandmail.comRoche (OTCMKTS:RHHBY) Upgraded by Morgan Stanley to Equal Weight RatingApril 24, 2026 | marketbeat.comRoche Holding AG (RHHBY) Q1 2026 Sales/Trading Call TranscriptApril 23, 2026 | seekingalpha.comRoche maintains outlook despite FX-driven sales drop in Q1April 23, 2026 | msn.comRHHBY's Q1 Results Hit by Currency Headwinds, Sales Up 6% at CERApril 23, 2026 | zacks.comRoche Backs Full-Year View as Quarterly Sales RiseApril 23, 2026 | wsj.comRoche Q1 sales down on forex effectsApril 23, 2026 | reuters.com[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss francApril 23, 2026 | globenewswire.comRoche MS Drug Cuts Relapses To Once Every 17 Years But Reports Eight DeathsApril 22, 2026 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNJ, RHHBY, and NVS Company DescriptionsJohnson & Johnson NYSE:JNJ$230.61 +0.19 (+0.08%) Closing price 05/14/2026 03:59 PM EasternExtended Trading$231.41 +0.80 (+0.35%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novartis NYSE:NVS$149.85 +0.10 (+0.07%) Closing price 05/14/2026 03:59 PM EasternExtended Trading$150.27 +0.42 (+0.28%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Roche OTCMKTS:RHHBY$51.29 +0.03 (+0.06%) As of 05/14/2026 03:59 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
